Ensayo de fase 3 que evalúa la seguridad y la eficacia de IMNN-001 administrada en combinación con quimioterapia estándar de NACT y adyuvante en pacientes recién diagnosticados con EOC avanzado, tubo de Falopio o cáncer peritoneal primario (OVATION-3)
Un ensayo aleatorizado de fase 3 que evalúa la seguridad y la eficacia de IP IMNN-001 administrado en combinación con quimioterapia estándar neoadyuvante y adyuvante en pacientes recién diagnosticados con EOC avanzado, tubo de Falopio o cáncer de peritoneal primario
This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Eligible participants will be randomly assigned 1:1 to receive either chemotherapy plus IMNN-001 or chemotherapy alone, followed by standard of care maintenance therapy.
Randomization will stratify by confirmed biomarker tumor homologous recombination deficiency status and stage of cancer.
On both arms, the chemotherapy regimen will consist of paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1 of each cycle. This will be repeated every 3 weeks for a total of 6 cycles, 3 in the neoadjuvant period and 3 in the adjuvant period following interval debulking surgery (IDS). On the experimental arm, IMNN-001 at a dose of 100 mg/m2 will be administered IP on Days 8 and 15 of the first chemotherapy cycle and then on Days 1, 8, and 15 of all subsequent 5 chemotherapy cycles for a total of 17 treatments in the neoadjuvant and adjuvant settings. When given on the same day as chemotherapy, IMNN-001 should be given at least 30 minutes after completion of carboplatin infusion. IDS will take place after 3 cycles of neoadjuvant chemotherapy (NACT) + IMNN-001 for 8 doses. Additional cycles of NACT are allowed at the discretion of the investigator but with discussion with the medical monitor.
An independent Data Monitoring Committee (iDMC) will monitor participants' safety and study conduct throughout the course of the trial.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Douglas Faller, M.D.
- Número de teléfono: +1 609 896 9100
- Correo electrónico: dfaller@imunon.com
Copia de seguridad de contactos de estudio
- Nombre: Lauren Musso
- Número de teléfono: +1 609 896 9100
- Correo electrónico: lmusso@imunon.com
Ubicaciones de estudio
-
-
Florida
-
Orlando, Florida, Estados Unidos, 32804
- Reclutamiento
- Advent Health
-
Investigador principal:
- Robert Holloway, MD
-
Contacto:
- Karla Hernandez-Cruz
- Correo electrónico: Karla.Hernandez-Cruz@AdventHealth.com
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70112
- Reclutamiento
- Louisiana State University HSC - NO Cancer Center
-
Contacto:
- Paige Chapman
- Número de teléfono: 504-210-1848
- Correo electrónico: pchap1@lsuhsc.edu
-
Investigador principal:
- Amelia Jernigan, M.D.
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- Reclutamiento
- Karmanos Cancer Institute
-
Contacto:
- Rachael Barry
- Número de teléfono: 313-576-9385
- Correo electrónico: barryr@karmanos.org
-
Investigador principal:
- Robert Morris, M.D.
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- Reclutamiento
- Masonic Cancer Center, University of Minnesota
-
Contacto:
- Safiya Easthausen
- Correo electrónico: easth017@umn.edu
-
Investigador principal:
- Melissa Geller, M.D.
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Reclutamiento
- Washington University School of Medicine in St. Louis
-
Investigador principal:
- Andrea Hagemann, MD
-
Contacto:
- Missy Bradlo
- Correo electrónico: bradlom@wustl.edu
-
-
New York
-
Rochester, New York, Estados Unidos, 14642
- Reclutamiento
- University of Rochester Medical Center
-
Contacto:
- Mckenzie McLoughlin
-
Investigador principal:
- Richard Moore, M.D.
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97213
- Reclutamiento
- Providence Cancer Institute
-
Contacto:
- Nora Auston
- Correo electrónico: Nora.Auston@providence.org
-
Investigador principal:
- Christopher Darus, MD
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57104
- Reclutamiento
- Sanford Health
-
Investigador principal:
- Maria Bell, MD
-
Contacto:
- Ashley Johnson
- Correo electrónico: ashley.johnson9@sanfordhealth.org
-
-
Tennessee
-
Chattanooga, Tennessee, Estados Unidos, 37403
- Reclutamiento
- Erlanger Health
-
Investigador principal:
- Stephen DePasquale, MD
-
Contacto:
- Kimberly Donelson
- Correo electrónico: kimberly.donelson@erlanger.org
-
Contacto:
- Lorraine Christensen
- Correo electrónico: lorraine.christensen@erlanger.org
-
-
Washington
-
Spokane, Washington, Estados Unidos, 99204
- Reclutamiento
- Providence Sacred Heart Medical Center & Children's Hospital
-
Investigador principal:
- Melanie Bergman, MD
-
Contacto:
- Jodie Mactagone
- Correo electrónico: jodie.mactagone@providence.org
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Reclutamiento
- Froedtert and The Medical College of Wisconsin
-
Investigador principal:
- William Bradley, MD
-
Contacto:
- Maia Terashvili
- Correo electrónico: mterashv@mcw.edu
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Participants must be female, ≥18 years of age, able to understand the study procedures, and agree to participate in the study by providing written informed consent.
-
Participants with a histologically confirmed diagnosis of high-grade non-mucinous epithelial ovarian (serous, endometrioid, carcinosarcoma, mixed epithelial pathologies), fallopian tube or peritoneal cancer that is Stage IIIB/C or IV according to the International Federation of Gynecology and Obstetrics (FIGO) or tumor, node and metastasis staging criteria.
-
Participants eligible to receive neoadjuvant chemotherapy.
-
Participants will provide a tumor tissue sample at pre-screening or screening, via laparoscopy or image guided core biopsy for determination of confirmed biomarker tumor status (HRD vs. HRP). See biomarker status definitions in the section below.
-
Participants of childbearing potential must have a negative serum pregnancy test (beta human chorionic gonadotropin) within 14 days prior to initiation of protocol therapy and be practicing an effective form of contraception. If applicable, participants must discontinue breastfeeding prior to study entry.
-
Participants must have adequate:
- Bone marrow function: Absolute neutrophil count (ANC) greater than or equal to 1,500/µl. Exceptions may be made in patients with benign ethnic neutropenia >800/ul with approval of a medical monitor. This ANC cannot have been induced or supported by granulocyte colony stimulating factors. Platelets greater than or equal to 100,000/µl.
- Renal function: eGFR > 60 ml/min/1.73m2
- Hepatic function: Bilirubin ≤ 1.5 x ULN. SGOT (AST) and SGPT (ALT) ≤ 3.0 x ULN and alkaline phosphatase ≤ 2.5 x ULN. Exceptions due to hepatic metastases can be considered in consultation with medical monitor.
- Neurologic function: Neuropathy (sensory and motor) less than or equal to Grade 1 as defined by CTCAE version 5.0.
-
Participants must have an ECOG score of 0, 1 or 2.
-
Participants should be free of active infection requiring parenteral antibiotics or a serious uncontrolled medical illness or disorder within 4 weeks of study entry.
-
Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to the first treatment. Continuation of hormone replacement therapy is permitted.
Exclusion Criteria:
- Participant who has received prior treatment with IMNN-001.
- Participant who has received oral or parenteral corticosteroids (>10 mg prednisone) within 2 weeks of first dose of IMNN-001 (if applicable) or who have a clinical requirement for ongoing systemic immunosuppressive therapy such as chronic steroid use not related to chemotherapy administration.
- Participant has mucinous, germ cell, transitional cell, clear cell, undifferentiated, or non-epithelial ovarian cancer.
- Participant has low-grade or Grade 1 epithelial ovarian cancer.
- Participant of childbearing potential, not practicing adequate contraception, participant who is pregnant, or participant who is breastfeeding are not eligible for this trial.
- Participant has a bowel obstruction by clinical symptoms or computed tomography (CT) scan, sub-occlusive mesenteric disease, abdominal or gastrointestinal fistula, gastrointestinal perforation, or intra-abdominal abscess.
- Participant has been diagnosed and/or treated with any therapy for invasive cancer <3 years from study enrollment, completed adjuvant chemotherapy and/or targeted therapy at least 3 years from enrollment, or completed adjuvant hormonal therapy less than 4 weeks from enrollment.
- Participant with definitively treated non-invasive malignancies such as cervical carcinoma in situ, ductal carcinoma in situ, grade 1 or 2 Stage IA endometrioid endometrial cancer, or non-melanomatous skin cancer are allowed.
- Participant with concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or expose the participant to extreme risk or decreased life expectancy.
- Participant has known active hepatitis or HIV with detectable viral load.
- Participant has a known contraindication or uncontrolled hypersensitivity to the components of paclitaxel, carboplatin, IMNN-001, or their excipients.
- Prior treatment for high-grade non-mucinous epithelial ovarian, fallopian tube, or peritoneal cancer (e.g., immunotherapy, anticancer therapy, surgery, radiation therapy).
- Participant is receiving treatment for active autoimmune disease. "Active" refers to any condition currently requiring therapy. Examples of autoimmune disease include systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis.
- Participant who has received prior radiotherapy to any portion of the abdominal cavity or pelvis is excluded. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, if it was completed at least 3 years prior to registration, and the participant remains free of recurrent or metastatic disease.
- Participant who has received prior chemotherapy for any abdominal or pelvic tumor is excluded. Participant may have received prior adjuvant chemotherapy for localized breast cancer, if it was completed at least three years prior to registration, and that the participant remains free of recurrent or metastatic disease.
- Participant with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study.
- Participant who will receive bevacizumab with the neoadjuvant or adjuvant treatment, or as maintenance will be excluded.
- Participant with any condition/anomaly that would interfere with the appropriate placement of the IP catheter for study drug administration including abdominal surgery within 4 weeks of study entry (for reason other than IP port placement or laparoscopic diagnosis of epithelial ovarian cancer), intestinal dysfunction as defined in #6 above.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Experimental Arm: IMNN-001 + SOC Chemotherapy + SOC Maintenance Therapy
IMNN-001 in combination with standard neoadjuvant and adjuvant chemotherapy followed by standard of care maintenance therapy |
100 mg/m2 IP given weekly during frontline treatment
Otros nombres:
175 mg/m2 IV given every 21 days for 6 cycles during frontline treatment AUC 6 IV given every 21 days for 6 cycles during frontline treatment Olaparib (300 mg orally every 12 hours for 2 years) for patients with somatic or germline BRCAmut.
Otros nombres:
Niraparib (200-300 mg orally daily for 3 years; dosing based on participant's weight and platelet counts) for either HRD/BRCAmut & HRD/BRCAwt.
Otros nombres:
|
|
Comparador activo: Control Arm: SOC Chemotherapy + SOC Maintenance Therapy
Standard neoadjuvant and adjuvant chemotherapy followed by standard of care maintenance therapy. |
175 mg/m2 IV given every 21 days for 6 cycles during frontline treatment AUC 6 IV given every 21 days for 6 cycles during frontline treatment Olaparib (300 mg orally every 12 hours for 2 years) for patients with somatic or germline BRCAmut.
Otros nombres:
Niraparib (200-300 mg orally daily for 3 years; dosing based on participant's weight and platelet counts) for either HRD/BRCAmut & HRD/BRCAwt.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall Survival
Periodo de tiempo: 48 months
|
Overall Survival is defined as the time (in months) from the date of randomization to the date of death by any cause. |
48 months
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Chemotherapy Response Score
Periodo de tiempo: 12 weeks
|
After the interval debulking surgery takes place, participants will be assessed for a chemotherapy response score by the pathologist and scored based on CRS3, CRS2, or CRS1. |
12 weeks
|
|
Surgical Response
Periodo de tiempo: 12 weeks
|
After the interval debulking surgery takes place, participants are scored in terms of their interval debulking status with a score of R0, R1, or R2. |
12 weeks
|
|
Time to Second Line Treatment
Periodo de tiempo: 13 months
|
Time to second line treatment is defined as the time (in months) from the date of randomization to the date of second line chemotherapy treatment or death, whichever occurs first. |
13 months
|
|
Objective Response Rate
Periodo de tiempo: 12 weeks
|
Objective Response Rate is defined as the proportion of participants with objective evidence of CR or PR prior to IDS. The evaluation of objective response rate will be based on investigator (site) assessment of the images following RECIST v1.1 criteria. |
12 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Silla de estudio: Premal H Thaker, M.D., Washington University School of Medicine
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Enfermedades del sistema endocrino
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Neoplasias por tipo histológico
- Enfermedades Genitales Femeninas
- Neoplasias de glándulas endocrinas
- Neoplasias Glandulares y Epiteliales
- Enfermedades Ováricas
- Enfermedades anexiales
- Neoplasias Genitales Femeninas
- Trastornos gonadales
- Carcinoma
- Enfermedades de las trompas de Falopio
- Carcinoma Epitelial De Ovario
- Neoplasias Ováricas
- Neoplasias de las trompas de Falopio
- Químicos orgánicos
- Hidrocarburos
- Cicloparafinas
- Hidrocarburos, alicíclicos
- Hidrocarburos, cíclico
- Terpenos
- Complejos de coordinación
- Taxaides
- Ciclodecanos
- Diterpenos
- Carboplatino
- Paclitaxel
- niraparib
- olaparib
- Gen-1
Otros números de identificación del estudio
Otros números de identificación del estudio
- 201-24-301
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .